Entrada Therapeutics, Inc.
TRDA
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dyā¦ read more
Healthcare
Biotechnology
4 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$6.79
Price+0.30%
$0.02
1Y
Price
Market Cap
$263.592m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-2617.7%
EBITDA Margin-2734.4%
Net Profit Margin-1743.6%
Free Cash Flow Margin-2617.7%
EBITDA Margin-2734.4%
Net Profit Margin-1743.6%
Free Cash Flow MarginRevenue
$5.738m
-70.8%
1y CAGR-2.5%
3y CAGR-1.9%
5y CAGREarnings
-$166.118m
-257.6%
1y CAGR+305.7%
3y CAGR+208.0%
5y CAGREPS
-$4.00
-248.2%
1y CAGR+261.5%
3y CAGR+177.6%
5y CAGRBook Value
$270.854m
$335.518m
Assets$64.664m
Liabilities$49.750m
DebtDebt to Assets
14.8%
-0.5x
Debt to EBITDAFree Cash Flow
-$131.641m
-190.3%
1y CAGR-28.3%
3y CAGR-39.8%
5y CAGRNo items found.
Press Releases
Statements and updates from the company